Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Portola Pharmaceuticals (PTLA) PT Raised to $50 at Citi
March 4, 2019 6:58 AM ESTCiti analyst Yigal Nochomovitz raised the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $50.00 (from $49.00) while maintaining a Buy rating as the company launches Andexxa. Nochomovitz is being executed well under the new CEOs leadership and should be owned as path to Andexxa growth is... More
Portola Pharma (PTLA) Misses Q4 EPS by 23c
March 1, 2019 8:08 AM ESTPortola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($1.34), $0.23 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $15.3 million versus the consensus estimate of $10.94 million.
For earnings history and earnings-related data on Portola Pharma (PTLA) click here.
... More